→ A decorated GLP-1 pioneer is retiring at Novo Nordisk. Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on

A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.

Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the goal of roughly tripling their footprint